We recently published a list of the 7 Most Undervalued Biotech Stocks To Invest In. In this article, we are going to take a ...

Biogen also has a biosimilars segment producing generic drugs with a 4% YoY revenue growth ... and none of the big name stocks were on the list. They believe these five stocks are the five ...

Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with late AMRAMR is a ...

The drug will launch within a week, it said, with no news yet on pricing, although Biogen did tell Reuters ... taurursodiol), which launched with a list price of $158,000 per year as an option ...

She added that patients treated with the oral drug in the trial ... launched with a list price of approximately $370,000 per year. It is viewed as a key product for Biogen after a series of ...

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against the ...

Felzartamab is still an investigational drug that has not yet received regulatory ... indicate financial burdens or cash flow concerns for Biogen. The press release emphasizes the limited ...

Biogen Inc. (Nasdaq: BIIB) – announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and safety of the investigational drug ...

Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with late AMRAMR is a leading cause of kidney transplant loss, with approximately ...